scholarly journals Botulinum Toxin-A Therapy in Pediatric Urology: Indications for the Neurogenic and Non-Neurogenic Neurogenic Bladder

2009 ◽  
Vol 9 ◽  
pp. 1300-1305 ◽  
Author(s):  
Lori Dyer ◽  
Israel Franco

Although, the role of Botulinum Toxin-A in the treatment of the neurogenic and non-neurogenic neurogenic bladder is becoming more defined, this is the first review article to characterize the emerging role of Botulinum Toxin-A in the pediatric urologic population. Injection of Botulinum Toxin-A at the level of the bladder works by inhibiting uninhibited bladder contractions and, possibly, by blocking some of the sensory nerve fibers. In children with sphincter dyssynergy, injection at the level of the urethral sphincter works by inhibiting the involuntary guarding reflex and blocking dyssynergic voiding.

2005 ◽  
Vol 173 (4S) ◽  
pp. 305-305
Author(s):  
Brigitte Schurch ◽  
Marianne de Seze ◽  
Pierre Denys ◽  
Emmanuel Chartier-Kastler ◽  
Francois Haab ◽  
...  

2012 ◽  
Vol 79 (19_suppl) ◽  
pp. 9-14
Author(s):  
Ubaldo Cantoro ◽  
Daniele Minardi ◽  
Vito Lacetera ◽  
Alessandro Conti ◽  
Francesco Catanzariti ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-5
Author(s):  
Antonio Marte ◽  
Micaela Borrelli ◽  
Maurizio Prezioso ◽  
Lucia Pintozzi ◽  
Pio Parmeggiani

We verified the efficacy and safety of botulinum toxin A (BTX-A) in treating bladder overactivity in children with neurogenic bladder (NB) secondary to myelomeningocele (MMC). Forty-seven patients (22, females; 25, males; age range, 5–17 years; mean age, 10.7 years) with poorly compliant/overactive neurogenic bladder on clean intermittent catheterization (CIC) and resistance or noncompliant to anticholinergics were injected with 200 IU of BTX-A intradetrusor. All patients experienced a significant 66.45% average increase of leak point volume (Wilcoxon paired rank test = 7.169 e-10) and a significant 118.57% average increase of specific bladder capacity at 20 cm H2O (Wilcoxon paired rank test = 2.466 e-12). Ten patients who presented with concomitant uni/bilateral grade II–IV vesicoureteral reflux were treated at the same time with Deflux. No patient presented with major perioperative or postoperative problems. Twenty-two patients needed a second and 18 a third injection of BTX-A after 6–9 months for the reappearance of symptoms. After a mean follow-up of 5.7 years, 38 out of 47 patients achieved dryness between CICs, and 9 patients improved their incontinence but still need pads. Our conclusion is that BTX-A represents a viable alternative to more invasive procedure in treatment of overactive NB secondary to MMC.


2019 ◽  
Vol 9 (1) ◽  
pp. 1-6
Author(s):  
Christos Farazi-Chongouki ◽  
Dimitrios Filippou

Sign in / Sign up

Export Citation Format

Share Document